** Shares of drugmaker TG Therapeutics TGTX.O rise 5.9% to $29.31 premarket
** Co forecasts preliminary Q4 net product revenue of $103.6 mln vs analysts' avg. est. of $97.69 mln - data compiled by LSEG
** Sees full-year 2024 net product revenue of $310 mln, above est. of $304.1 mln
** TGTX expects to end 2024 with cash position of about $310 mln
** Co forecasts 2025 total revenue of about $540 mln vs est. of $549.5 mln
** Up to last close, stock had risen 62.5% in past 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.